DGCR6 Inhibitors
DGCR6 inhibitors refer to a class of chemical compounds that specifically target and modulate the activity of the DGCR6 (DiGeorge syndrome critical region gene 6) protein. DGCR6 is encoded within the chromosomal region 22q11.2 and is involved in various cellular processes, including gene expression regulation and chromatin remodeling. Structurally, DGCR6 is related to the Drosophila gonadal (gdl) protein, suggesting potential roles in growth or development, though the precise biological mechanisms are still under active research. Inhibitors of DGCR6 are designed to interfere with its function by binding to the protein, thereby modulating its ability to interact with other molecules or participate in cellular pathways. This inhibition is typically achieved through chemical structures that have high affinity for the active or allosteric sites on DGCR6, blocking its normal biological activity.
The chemical nature of DGCR6 inhibitors can vary widely, but these compounds often exhibit structural features that enable them to achieve selective binding, minimizing off-target effects. Common strategies for designing DGCR6 inhibitors involve the use of molecular docking techniques to identify potential binding pockets and subsequent chemical modifications to optimize the interaction between the inhibitor and the target protein. These inhibitors may possess diverse chemical backbones, ranging from small organic molecules to larger peptide-based structures, depending on the specific requirements for DGCR6 interaction. Once bound, these inhibitors can alter downstream signaling or gene expression patterns, leading to changes in cellular function that are being studied for their broader biological implications. The development and refinement of DGCR6 inhibitors is an ongoing area of interest in molecular biology and chemical biology, as researchers seek to better understand the role of this protein in cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound induces DNA demethylation that could specifically lead to the hypomethylation of promoter regions upstream of the DGCR6 gene, potentially resulting in the suppression of its transcriptional initiation. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, through its inhibition of histone deacetylase, could cause an increase in acetylated histones near the DGCR6 gene locus, thereby condensing the chromatin structure and reducing the accessibility of transcription factors to the DGCR6 promoter. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A may decrease DGCR6 expression by preventing deacetylation of histones, leading to a chromatin conformation less conducive to the binding of transcriptional machinery to the DGCR6 gene. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid could repress DGCR6 expression by binding to retinoic acid receptors, which then interact with the regulatory regions of DGCR6, altering gene transcription dynamics and potentially reducing mRNA synthesis. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin can intercalate between DNA base pairs, potentially disrupting the binding of transcription factors and other regulatory proteins to DGCR6 gene promoter regions, leading to a decrease in its transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
By inhibiting the mTOR signaling pathway, rapamycin could downregulate DGCR6 expression as part of a broader response to reduced cell proliferation and protein synthesis. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA at transcription initiation complexes, which may obstruct RNA polymerase progression along the DGCR6 gene, reducing its RNA transcript levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide blocks peptide elongation during translation, which could lead to the destabilization of transcription factors necessary for DGCR6 expression, indirectly diminishing its mRNA levels. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
By binding to GC-rich sequences in the DNA, Mithramycin A could directly inhibit the transcription of the DGCR6 gene by disrupting the necessary contact between the gene's promoter region and transcriptional activators. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine disrupts lysosomal acidification, which can lead to the alteration of cellular signaling pathways that converge on the transcriptional repression of the DGCR6 gene, thereby reducing its expression. | ||||||